share_log

TRITON PACIFIC HEALTHCARE PARTNERS COMPLETES SALE OF BIOMATRIX SPECIALTY INFUSION PHARMACY

TRITON PACIFIC HEALTHCARE PARTNERS COMPLETES SALE OF BIOMATRIX SPECIALTY INFUSION PHARMACY

泰坦太平洋醫療合夥企業完成生物基質特殊輸液藥房的銷售
PR Newswire ·  06/25 11:00

LOS ANGELES, June 25, 2024 /PRNewswire/ -- Triton Pacific Healthcare Partners ("Triton Pacific"), a healthcare-focused private equity group, is pleased to announce the closing of its sale of BioMatrix Specialty Infusion Pharmacy ("BioMatrix" or the "Company") to Frazier Healthcare Partners. Terms of the transaction were not disclosed.

2024年6月25日,洛杉磯 /新華/ -- Triton Pacific Healthcare Partners(Triton Pacific),一家專注於醫療保健的私募股權集團,很高興宣佈已將BioMatrix Specialty Infusion Pharmacy(BioMatrix或公司)出售給Frazier Healthcare Partners。交易條款未披露。

BioMatrix, headquartered in Plantation, FL and serving patients across all 50 states, is one of the largest and most diversified independent providers of specialty infusion services in the U.S. The Company delivers a high-touch, patient-centric model built around therapeutic centers of excellence that provide superior management of patient therapies, including IVIG, bleeding disorders, immunology, neurology, transplant, oncology, and rare diseases.

總部位於佛羅里達州Plantation的BioMatrix,在美國爲服務全50個州的患者之一,並且是最大和最多元化獨立提供特殊輸液服務供應商之一。該公司建立了高接觸、以患者爲中心的模型,圍繞療效卓越的治療中心來提供優質的病人治療管理,包括IVIG、出血性疾病、免疫學、神經學、移植、腫瘤和罕見病等方面的治療。

Triton Pacific partnered with ACON Investments to acquire BioMatrix in 2016 and, during the course of the investment, worked with the Company to complete five strategic acquisitions. These acquisitions expanded the Company's therapy footprint, added management capabilities, afforded access to new payor contracts, expanded the drug portfolio, and built out infusion operations. In early 2023, BioMatrix divested its lower-margin traditional specialty business and focused intensively on specialty infusion, a high-growth sector propelled by compelling tailwinds. Successfully executing on this strategy, BioMatrix drove exceptional organic growth, with revenue growing roughly five times faster than the broader infusion industry. Throughout Triton Pacific's investment period, BioMatrix has undergone a meaningful evolution, but its commitment to patient care and improved outcomes has remained at the forefront throughout. With an elite management team led by Kathee Kramm and a stellar growth trajectory, BioMatrix is poised for continued success.

Triton Pacific於2016年與ACON Investments合作收購了BioMatrix,並在投資過程中與該公司合作完成了5個戰略性收購。 這些收購擴大了公司的治療範圍,增加了管理能力,爲新的付款人合同提供了便利,擴大了藥物組合,並構建了輸液運營。 2023年初,BioMatrix剝離了低利潤率的傳統特殊業務,集中精力發展特殊輸液業務,這是一個由趨勢支撐的高增長行業。成功地實施這一策略,BioMatrix推動了卓越的有機增長,收入增長大約比廣泛輸液行業快五倍。在Triton Pacific的投資期間,BioMatrix經歷了有意義的變革,但其致力於病人護理和改善結果的承諾始終處於前沿。由Kathee Kramm領導的精英管理團隊以及恒星幣的優秀增長軌跡,BioMatrix已經準備繼續取得成功。

Kathee Kramm, Chief Executive Officer for BioMatrix, states, "It has been a pleasure to work with Triton Pacific since joining BioMatrix in 2023. The combination of Triton, ACON, and the extremely talented, hardworking staff at BioMatrix have been instrumental in our rapid growth over the last 12 months. The culture at BioMatrix truly revolves around the patient and putting their needs above all else. I am extremely proud of where we are today and very excited to watch the organization continue to reach new highs and unprecedented levels of growth."

BioMatrix首席執行官Kathee Kramm表示:"自2023年加入BioMatrix以來,與Triton Pacific合作一直是一種享受。Triton、ACON以及BioMatrix非常有才華、勤奮的員工的結合,對我們在過去的12個月內實現快速增長起到了決定性的作用。 BioMatrix的文化確實圍繞患者展開,在患者需求之上,我爲我們今天的業績感到非常自豪,並且非常激動地看着組織繼續跨越新的高峰和前所未有的增長水平。"

Houlihan Lokey, led by Mike Pisani, served as the Company's financial advisor. DLA Piper, led by Josh Kaye, served as the Company's legal counsel.

Houlihan Lokey(由Mike Pisani領導)擔任該公司的財務顧問。DLA Piper(由Josh Kaye領導)擔任該公司的法律顧問。

About Triton Pacific

關於Triton Pacific

Triton Pacific Capital Partners ( founded in 2001, is a private equity firm offering unique investment opportunities to institutional and high net worth investors. Its healthcare division, Triton Pacific Healthcare Partners, has a dedicated healthcare investment team with a demonstrated track record of successfully sourcing, acquiring, and managing healthcare investments.

Triton Pacific Capital Partners(成立於2001年)是一家爲機構和高淨值投資者提供獨特投資機會的私募股權公司。其醫療保健部門Triton Pacific Healthcare Partners擁有一個專門的醫療保健投資團隊,具有成功地尋找、收購和管理醫療保健投資的業績記錄。

Contact:

Joseph I. Davis


Managing Partner


[email protected]

Brian Siegel,IRC,MBA-高級管理董事,Hayden IR,電話:(346)396-8696,ir@zedge.net

Joseph I. Davis


管理合夥人


[email protected]

SOURCE Triton Pacific

消息來源 Triton Pacific

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論